Drug reference
alirocumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Cardiovascular (Anti Hyperlipidemics)
Mechanism of action
Monoclonal antibody that binds to PCSK9 (proprotein convertase subtilisin/kexin type 9) ,LDL-C is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway, PCSK9 is a serine protease that destroys LDLR in the liver, resulting in decreased LDL-C clearance and increased plasma LDL-C
Common side effects
- Injection site reactions
- Nasopharyngitis
- Influenza
- Allergic reactions
Related conditions
Frequently asked questions
What drug class is alirocumab?
alirocumab belongs to: Cardiovascular.
How does alirocumab work?
Monoclonal antibody that binds to PCSK9 (proprotein convertase subtilisin/kexin type 9) ,LDL-C is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway, PCSK9 is a serine protease that destroys LDLR in the liver, resulting in decreased LDL-C clearance and increased plasma LDL-C
What are the common side effects of alirocumab?
Injection site reactions, Nasopharyngitis, Influenza, Allergic reactions
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.